J. García-Arriaza

H. Zetterberg, M. Esteban, J. García-Arriaza, 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1

C. Sorzano, R. Sanders, A. Cuervo, 2019, Front. Immunol..

Molecular Basis for a Lack of Correlation between Viral Fitness and Cell Killing Capacity

E. Domingo, N. Pariente, C. Escarmís, 2007, PLoS pathogens.

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen

J. J. Conesa, C. Sorzano, J. Carrascosa, 2015, PloS one.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC

S. Self, D. Montefiori, R. Gottardo, 2018, Journal of Virology.

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

C. Sorzano, M. Esteban, J. García-Arriaza, 2010, PloS one.

Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins

C. Muñoz-Fontela, M. Ustav, K. Ljungberg, 2018, Journal of Virology.

Eeyarestatin I, an inhibitor of the valosin-containing protein, exhibits potent virucidal activity against the flaviviruses.

J. García-Arriaza, Patricia Pérez, C. Ballesta, 2022, Antiviral research.

Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection

M. Esteban, J. García-Arriaza, J. Casasnovas, 2022, Frontiers in Immunology.

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

P. Roques, N. Tchitchek, K. Ljungberg, 2017, JCI insight.

The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses

J. Saiz, C. Sorzano, M. Martín-Acebes, 2021, Emerging microbes & infections.

A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection

C. Sorzano, P. Liljeström, M. Esteban, 2014, Journal of Virology.

Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein

F. Lemonnier, M. Esteban, J. García-Arriaza, 2017, PLoS neglected tropical diseases.

Viruses as Quasispecies: Biological Implications

E. Domingo, C. Perales, V. Martín, 2006, Current topics in microbiology and immunology.

New Vaccine Design Based on Defective Genomes That Combines Features of Attenuated and Inactivated Vaccines

E. Domingo, C. Escarmís, J. García-Arriaza, 2010, PloS one.

A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness.

E. Domingo, C. Escarmís, J. García-Arriaza, 2005, Virology.

Poxvirus vectors as HIV/AIDS vaccines in humans

M. Esteban, J. García-Arriaza, B. Perdiguero, 2012, Human vaccines & immunotherapeutics.

Quasispecies dynamics and evolution of foot-and-mouth disease virus.

E. Domingo, C. M. Ruiz-Jarabo, F. Sobrino, 2004 .

Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens

C. Sorzano, M. Esteban, J. García-Arriaza, 2014, Journal of Virology.

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

C. Sorzano, M. Esteban, J. García-Arriaza, 2013, PloS one.

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

C. Sorzano, T. Calandra, T. Roger, 2011, PloS one.

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

C. Sorzano, M. Esteban, J. García-Arriaza, 2010, PloS one.

Enhancing poxvirus vectors vaccine immunogenicity

M. Esteban, J. García-Arriaza, 2014, Human vaccines & immunotherapeutics.

Prime-Boost Immunization Strategies against Chikungunya Virus

L. Ng, P. Roques, P. Liljeström, 2014, Journal of Virology.

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost

M. Ustav, K. Ljungberg, P. Liljeström, 2018, Scientific Reports.

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice

J. Saiz, M. Martín-Acebes, M. Esteban, 2018, Scientific Reports.

Exploration of sequence space as the basis of viral RNA genome segmentation

E. Domingo, C. Perales, Elena Moreno, 2014, Proceedings of the National Academy of Sciences.

Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.

A. Admon, M. Esteban, J. García-Arriaza, 2021, Journal of proteome research.

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

H. Niphuis, M. Esteban, J. García-Arriaza, 2022, Frontiers in Immunology.

Clinical applications of attenuated MVA poxvirus strain

M. Esteban, J. García-Arriaza, B. Perdiguero, 2013, Expert review of vaccines.

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

B. Weynand, J. Neyts, M. Esteban, 2022, Frontiers in Immunology.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Prima

S. Self, D. Montefiori, R. Gottardo, 2017, Journal of Virology.

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

S. Self, D. Montefiori, G. Pantaleo, 2015, Journal of Virology.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

Felipe García, M. Plana, G. Pantaleo, 2011, Vaccine.

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B

C. Sorzano, M. Esteban, J. García-Arriaza, 2020, Vaccines.

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design

C. Sorzano, M. Esteban, J. García-Arriaza, 2019, Vaccines.

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization

Felipe García, M. Plana, J. Gatell, 2017, PloS one.

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.

B. Clotet, J. Martinez-Picado, C. Brander, 2015, The Journal of antimicrobial chemotherapy.

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens

Felipe García, M. Plana, J. Gatell, 2011, Journal of Virology.

Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

J. Lasarte, M. Esteban, J. García-Arriaza, 2023, Frontiers in Immunology.

Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence

Eilon Barnea, A. Admon, C. Palomo, 2019, PLoS neglected tropical diseases.

Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells.

Eilon Barnea, A. Admon, C. Palomo, 2019, Journal of proteome research.

Nearly Full-Length HCV Genome Vaccinia Virus Ankara Expressing the Candidate ( MVA-HCV ) Based on Modified a Novel Hepatitis C Virus ( HCV ) Vaccine byCell Immune Responses Induced in Mice High , Broad , Polyfunctional , and Durable T

C. Sorzano, J. García-Arriaza, B. Perdiguero, 2013 .

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

C. Brander, Felipe García, J. Gatell, 2015, PloS one.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in 1 humans triggers robust, polyfunctional and selective effector memory T cell 2

Felipe García, J. Gatell, J. García-Arriaza, 2011 .

Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins

J. Ávila, F. Hernández, M. Esteban, 2020, Vaccines.

Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy

M. Esteban, J. García-Arriaza, M. García‐Ayllón, 2022, Frontiers in Immunology.

Virological and Immunological Characterization of Novel Nyvac- Based Hiv/aids Vaccine Candidates Expressing Clade C Trimeric Soluble Gp140(zm96) and Gag(zm96)-pol-nef(cn54) as Virus-like Particles the Generation of Vaccines against Hiv/aids Able to Induce Long-lasting Protective Immunity Remains a M

G. Pantaleo, C. Sorzano, T. Calandra, 2022 .

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus

M. Esteban, J. García-Arriaza, D. López, 2021, Biomedicines.

Ankara Expressing HIV-1 Antigens Immunogenicity of Modified Vaccinia Virus Encoding an Inhibitor of IRF3 Improves the Deletion of the Vaccinia Virus N2L Gene

M. Esteban, J. García-Arriaza, C. E. Gómez, 2014 .

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

C. del Fresno, M. Esteban, J. García-Arriaza, 2021, Journal of Virology.

Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant

C. Sorzano, M. Bécares, Susana Guerra, 2020, Journal of virology.

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression

C. Sorzano, M. Esteban, J. García-Arriaza, 2018, bioRxiv.

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

M. Muñoz-Fernández, M. Esteban, J. García-Arriaza, 2012, Virus research.

MVA-CoV2-S vaccine candidate confers full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice

J. López-Barneo, R. Ramírez-Lorca, A. Pascual, 2022 .

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses

G. Pantaleo, C. Sorzano, R. Wagner, 2019, Front. Immunol..

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara

J. Saiz, M. Martín-Acebes, M. Esteban, 2022, Pharmaceuticals.

Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate

J. López-Barneo, R. Ramírez-Lorca, A. Pascual, 2023, Nature Neuroscience.

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice

J. Saiz, M. Martín-Acebes, M. Esteban, 2018, Scientific Reports.

Highly attenuated poxvirus-based vaccines against emerging viral diseases

L. Marcos-Villar, J. García-Arriaza, B. Perdiguero, 2023, Journal of molecular biology.

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

M. Esteban, J. García-Arriaza, J. Casasnovas, 2022, NPJ vaccines.

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

L. Marcos-Villar, J. García-Arriaza, B. Perdiguero, 2023, Journal of Molecular Biology.

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

M. Esteban, J. García-Arriaza, J. Casasnovas, 2022, Frontiers in Immunology.

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

Natalia Vicente, C. Suay-Corredera, M. Pricolo, 2021, Frontiers in Immunology.

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization

Felipe García, M. Plana, J. Gatell, 2018, PloS one.

Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes.

E. Domingo, C. Escarmís, J. García-Arriaza, 2006, Journal of molecular biology.

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost

M. Ustav, K. Ljungberg, P. Liljeström, 2018, Scientific Reports.

Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

G. Pantaleo, C. Sorzano, T. Calandra, 2014, Journal of Virology.

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

M. Muñoz-Fernández, M. Esteban, J. García-Arriaza, 2012, Virus Research.

A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection

C. Sorzano, P. Liljeström, M. Esteban, 2014, Journal of Virology.

Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.

A. Gómez-Carballa, F. Martinón-Torres, I. Rivero-Calle, 2023, Antiviral research.